Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $1.4M | $20.7M | $30.3M | $4.3M | $8M | |
| Gross Profit | -$52.3M | -$63.7M | -$18.5M | -$6.5M | -$3.3M | |
| Operating Income | -$198.3M | -$230.9M | -$167.8M | -$45.6M | -$47M | |
| EBITDA | -$184.1M | -$170.7M | -$133.6M | -$39.7M | -$37.6M | |
| Diluted EPS | -$1.45 | -$1.62 | -$0.81 | -$0.30 | -$0.27 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $342.5M | $354M | $375.7M | $224M | $588.6M | |
| Total Assets | $415.4M | $467.6M | $519.9M | $448M | $913.7M | |
| Current Liabilities | $15.5M | $17.5M | $44.1M | $59.5M | $60.6M | |
| Total Liabilities | $91.7M | $109.3M | $267.5M | $277.8M | $616.6M | |
| Total Equity | $323.7M | $358.3M | $252.5M | $170.2M | $297.1M | |
| Total Debt | $9.3M | $8.4M | $174.6M | $183.1M | $529.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$99.2M | -$119.9M | -$84.3M | -$30.7M | -$25.5M | |
| Cash From Investing | -$136.9M | $4M | -$355.6M | -$4.5M | -$248.1M | |
| Cash From Financing | $157.9M | $46.4M | $577.3M | -$864K | $473.4M | |
| Free Cash Flow | -$137.1M | -$208.5M | -$117.8M | -$50.2M | -$28.5M | |
Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.
In the current month, ENVX has received 9 Buy ratings 2 Hold ratings, and 0 Sell ratings. The ENVX average analyst price target in the past 3 months is $26.90.
According to analysts, the consensus estimate is that Enovix Corp. share price will rise to $26.90 per share over the next 12 months.
Analysts are divided on their view about Enovix Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Enovix Corp. is a Sell and believe this share price will drop from its current level to $10.00.
The price target for Enovix Corp. over the next 1-year time period is forecast to be $26.90 according to 11 Wall Street analysts, 9 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
According to Wall Street analysts, the consensus rating for Enovix Corp. is a Buy. 9 of 11 analysts rate the stock a Buy at this time.
You can purchase shares of Enovix Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Enovix Corp. shares.
Enovix Corp. was last trading at $8.27 per share. This represents the most recent stock quote for Enovix Corp.. Yesterday, Enovix Corp. closed at $8.27 per share.
In order to purchase Enovix Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Signup to receive the latest stock alerts
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Market Cap: $4.6T
P/E Ratio: 64x
Market Cap: $4T
P/E Ratio: 37x
Market Cap: $3.8T
P/E Ratio: 39x
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.